Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.87 +10.7%	$1.55	$1.05 ▼ $5.17	$183.08M	0.3	1.42 million shs	1.61 million shs
CCCC C4 Therapeutics	$2.46 +4.7%	$1.92	$1.09 ▼ $7.22	$167.25M	2.97	1.65 million shs	1.16 million shs
DERM Journey Medical	$6.95 -4.3%	$7.15	$3.54 ▼ $8.90	$169.13M	0.8	175,392 shs	267,426 shs
VTVT vTv Therapeutics	$15.85 +3.6%	$15.55	$12.62 ▼ $26.99	$48.88M	0.57	1,339 shs	859 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+10.65%	+14.72%	+18.35%	+42.75%	+59.83%
CCCC C4 Therapeutics	+4.68%	-1.60%	+21.78%	+78.26%	-56.61%
DERM Journey Medical	-4.27%	-8.19%	-3.47%	+0.29%	+46.01%
VTVT vTv Therapeutics	+3.59%	+12.37%	-6.71%	-24.63%	+19.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.6053 of 5 stars	3.6	3.0	1.8	1.7	0.6
CCCC C4 Therapeutics	1.6003 of 5 stars	3.2	2.0	1.6	1.7	0.0
DERM Journey Medical	1.8794 of 5 stars	3.5	1.0	2.2	0.8	0.6
VTVT vTv Therapeutics	1.6988 of 5 stars	3.5	3.0	1.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	366.00% Upside
CCCC C4 Therapeutics	2.33	Hold	$8.00	225.20% Upside
DERM Journey Medical	3.00	Buy	$10.83	55.88% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	123.97% Upside

Current Analyst Ratings Breakdown

Latest VTVT, CCCC, ACRS, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $13.00
8/13/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$16.79M	12.07	N/A	N/A	$1.22 per share	1.53
CCCC C4 Therapeutics	$35.58M	4.92	N/A	N/A	$2.45 per share	1.00
DERM Journey Medical	$56.13M	2.88	N/A	N/A	$0.83 per share	8.37
VTVT vTv Therapeutics	$1.02M	49.57	N/A	N/A	$0.75 per share	21.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.37	N/A	N/A	N/A	-802.03%	-34.01%	-24.18%	N/A
CCCC C4 Therapeutics	-$105.32M	-$1.58	N/A	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	N/A
VTVT vTv Therapeutics	-$18.46M	-$3.01	N/A	∞	N/A	N/A	-179.75%	-55.91%	N/A

Latest VTVT, CCCC, ACRS, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/12/2025	Q2 2025	VTVT vTv Therapeutics	-$0.85	-$0.92	-$0.07	-$0.92	N/A	N/A
8/7/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$1.34 million	$1.78 million
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.88	3.88
CCCC C4 Therapeutics	N/A	5.06	5.06
DERM Journey Medical	1.11	1.27	1.03
VTVT vTv Therapeutics	N/A	4.98	7.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CCCC C4 Therapeutics	78.81%
DERM Journey Medical	7.25%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	5.60%
CCCC C4 Therapeutics	8.73%
DERM Journey Medical	15.03%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.33 million	102.27 million	Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
VTVT vTv Therapeutics	9	3.19 million	3.06 million	Not Optionable

VTVT, CCCC, ACRS, and DERM Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Receives Buy Rating from HC Wainwright

August 15 at 2:51 AM | americanbankingnews.com

vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 7:47 AM | finanznachrichten.de

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025 | finanznachrichten.de

vTv Therapeutics Receives Notice of Allowance for Cadisegliatin Patent, Strengthening Protection for Type 1 Diabetes Treatment

August 11, 2025 | quiverquant.comQ

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025 | globenewswire.com

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

August 7, 2025 | globenewswire.com

vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Below 50 Day Moving Average - Here's Why

July 26, 2025 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving Average - Time to Sell?

July 17, 2025 | marketbeat.com

vTv Therapeutics Inc (VTVT) Share Chat - Investing.com UK

June 29, 2025 | uk.investing.com

VTVT - vTv Therapeutics Inc Class A Chart - Morningstar

June 27, 2025 | morningstar.comM

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025 | globenewswire.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.comT

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.comQ

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, CCCC, ACRS, and DERM Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.87 +0.18 (+10.65%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.81 -0.06 (-3.21%)

As of 08/15/2025 07:57 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

C4 Therapeutics NASDAQ:CCCC

$2.46 +0.11 (+4.68%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.46 0.00 (0.00%)

As of 08/15/2025 06:51 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Journey Medical NASDAQ:DERM

$6.95 -0.31 (-4.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.61 -0.34 (-4.95%)

As of 08/15/2025 07:46 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

vTv Therapeutics NASDAQ:VTVT

$15.85 +0.55 (+3.59%)

Closing price 08/15/2025 03:55 PM Eastern

Extended Trading

$15.85 0.00 (0.00%)

As of 08/15/2025 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time